A Practical Approach, Second Edition=Ronald D. Ho.pdf

870 DEVELOPMENTAL REPRODUCTIVE TOXICOLOGY: A PRACTICAL APPROACH, SECOND EDITION58. Selevan, S.G., Rice, D.C., Hogan, K.A., Euling, S.Y., Pfahles-Hutchens, A., and Bethel, J., Bloodlead concentration and delayed puberty in girls, New Engl. J. Med., 348, 1527, 2003.59. Wu, T., Buck, G.M., and Mendola, P., Blood lead levels and sexual maturation in U.S. girls: The ThirdNational Health and Nutrition Examination Survey, 1988–1994, Environ. Health Perspect., 111, 737, 2003.60. Silva, E., Rajapakse, N., and Kortenkamp, A., Something from “nothing” — eight weak estrogenicchemicals combined at concentrations below NOECs produce significant mixture effects, Environ.Sci. Technol., 36, 1751, 2002.61. Selevan, S.G., Kimmel, C.A., and Mendola, P., Eds., Identifying critical windows of exposure forchildren’s health, Environ. Health Perspect., 108(Suppl 3), 449, 2000.62. U.S. Environmental Protection Agency, Endocrine Disruptor Screening and Testing Advisory CommitteeFinal Report, EPA/743/R-98/003, August 1998; available at http://www.epa.gov/scipoly/oscpendo/history/finalrpt.htm.63. National Toxicology Program, Report of the Endocrine Disruptors Low-Dose Peer Review, August2001; available at http://ntp-server.niehs.nih.gov/htdocs/liason/LowDosePeerFinalRpt.pdf.64. Euling, S.Y., Gennings, C., Wilson, E.M., Kemppainen, J.A., Kelce, W.R., and Kimmel, C.A.,Response-surface modeling of the effect of 5-dihydrotestosterone and androgen receptor levels on theresponse to the androgen antagonist vinclozolin, Toxicol. Sci., 69, 332, 2002.65. Wolf, C.J., LeBlanc, G.A., Ostby, J.S., and Gray, L.E., Jr., Characterization of the period of sensitivityof fetal male sexual development to vinclozolin, Toxicol. Sci., 55, 152, 2000.66. vom Saal, F.S., Timms, B.G., Montano, M.M., Palanza, P., Thayer, K.A., Nagel, S.C., Dhar, M.D.,Ganjam, V.K., Parmigiani, S., and Welshons, W.V., Prostate enlargement in mice due to fetal exposureto low doses of estradiol or diethylstilbestrol and opposite effects at high doses, Proc. Natl. Acad.Sci. USA, 94, 2056, 1997.67. Kohn, M.C. and Melnick, R.L., Biochemical origins of the non-monotonic receptor-mediated doseresponse,J. Mol. Endocrinol., 29, 113, 2002.68. Almstrup, K., Fernandez, M.F., Petersen, J.H., Olea, N., Skakkebaek, N.E., and Leffers, H., Dualeffects of phytoestrogens result in u-shaped dose-response curves, Environ. Health Perspect., 110,743, 2002.69. Gaido, K.W., Maness, S.C., McDonnell, D.P., Dehal, S.S., Kupfer, D., and Safe, S., Interaction ofmethoxychlor and related compounds with estrogen receptor alpha and beta, and androgen receptor:structure-activity studies, Mol. Pharmacol., 58, 852, 2000.70. Slikker, W. Jr., Anderson, M.E., Bogdanffy, M.S., Bus, J.S., Cohen, S.D., Conolly, R.B., David, R.M.,Doerrer, N.G., Dorman, D.C., Gaylor, D.W., Hattis, D., Rogers, J.M., Setzer, R.W., Swenberg, J.A.,and Wallace, K., Dose-dependent transitions in mechanisms of toxicity, Toxicol. Appl. Pharmacol.,15, 203, 2004.71. Kimmel, C.A. and Francis, E.Z., Proceedings of the workshop on the acceptability and interpretationof dermal developmental toxicity studies, Fundam. Appl. Toxicol., 14, 386, 1990.72. Kimmel, C.A. and Young, J.F., Correlating pharmacokinetics and teratogenic endpoints, Fundam.Appl. Toxicol., 3, 250, 1983.73. Clarke, D.O., Duignan, J.M., and Welsch, F., 2-Methoxyacetic acid dosimetry-teratogenicity relationshipsin CD-1 mice exposed to 2-methoxyethanol, Toxicol. Appl. Pharmacol., 114, 77, 1992.74. Nau, H., Teratogenic valproic acid concentrations: infusion by implanted minipumps vs conventionalinjection regimen in the mouse, Toxicol. Appl. Pharmacol., 80, 243, 1985.75. Nau, H., Species differences in pharmacokinetics, drug metabolism and teratogenesis, in Pharmacokineticsin Teratogenesis, Vol. 1, Nau, H. and Scott, W. J., Eds., CRC Press, Boca Raton, 1987, p. 81.76. Terry, K.K., Elswick, B.A., Stedman, D.B., and Welsch, F., Developmental phase alters dosimetryteratogenicityrelationship for 2-methoxyethanol in CD-1 mice, Teratology, 49, 218, 1994.77. McCarver, D.G. and Hines, R.N., The ontogeny of human drug-metabolizing enzymes: phase IIconjugation enzymes and regulatory mechanisms, J. Pharmacol. Exp. Ther., 300, 361, 2002.78. Cresteil, T., Onset of xenobiotic metabolism in children: toxicological implications, Food Addit.Contam., 15(Suppl), 45, 1998.79. Koukouritaki, S.B., Simpson, P., Yeung, C.K., Rettie, A.E., and Hines, R.N., Human hepatic flavincontainingmonooxygenases 1 (FMO1) and 3 (FMO3) developmental expression, Pediatr. Res., 51,236, 2002.© 2006 by Taylor & Francis Group, LLC